A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Eligibility Criteria

• * Participant must be 18 to 75 years of age inclusive.
• * BMI: ≥ 30 kg/m2, or ≥ 27 kg/m2 with at least one weight related comorbidity.
• * A stable, self-reported body weight for 3 months prior to screening.
• * Male and female participants: Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• * Female participants must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.
• * Capable of giving signed informed consent.
• * History of any clinically important disease or disorder, which, in the opinion of the Investigator, may put the participant at risk.
• * History or presence of GI, renal, hepatic disease.
• * Previous or planned bariatric surgery or fitting of a weight loss device.
• * Obesity induced by endocrine disorders such as Cushing's syndrome, insulinoma or Prader-Willi syndrome.
• * History of T1DM or T2DM or symptoms indicative of insulinopenia or poor glucose control.
• * HbA1c ≥ 6.5% (48 mmol/mol), fasting serum glucose ≥ 126 mg/dL (7.0 mmol/L) or random glucose ≥ 200 mg/dL (11.1 mmol/L).
• * Significant gastric and hepatobiliary disease.
• * History of acute or chronic pancreatitis or pancreatic amylase or lipase \> 2 × ULN at screening.
• * History of psychosis or bipolar disorder.
• * History of major depressive disorder within the 2 years prior to screening or depression.
• * Treatment with a GLP1 containing preparation, either as part of treatment or while participating in another clinical study within the 3 months or 5 half-lives of the drug prior to screening.
• * Vulnerable populations